In addition, the use of imiquimod to induce psoriasis in vitro in this study is relatively non-specific, and we expect to use K14-VEGF and K5-STST3C transgenic mouse models to further validate the therapeutic effect of EGT in psoriasis in the future. This evidence concerns the gene KRT14 and psoriasis.